Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group

Ying-Ying Leung, William Tillett, Maarten de Wit, Ana-Maria Orbai, Laura C Coates, Oliver FitzGerald, Philip S Helliwell, Vibeke Strand, Philip J Mease, Niti Goel, Robin Christensen, Joseph F Merola, Christine A Lindsay, Alexis Ogdie, Laure Gossec, Dafna D Gladman

Research output: Contribution to journal › Article › peer-review

4 Citations (SciVal)
71 Downloads (Pure)

Abstract

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) working group-comprising rheumatologists, dermatologists, methodologists, and patient research partners-provided updates at the GRAPPA 2022 annual meeting on its work to evaluate composite outcome measures for PsA. Ten composite outcome measures were considered. Initial steps were to define the population, the purpose of use, and the proposed pros and cons of the 10 candidate composite instruments for PsA. Preliminary Delphi exercises within the working group and GRAPPA stakeholders confirmed high priority for evaluating minimal disease activity (MDA); moderate priority for Disease Activity in PsA (DAPSA), American College of Rheumatology (ACR) response criteria, Psoriatic Arthritis Disease Activity Score (PASDAS), Composite Psoriatic Disease Activity Index (CPDAI), 3 visual analog scale (VAS), and 4VAS; and low priority for Disease Activity Score in 28 joints (DAS28), Psoriatic Arthritis Responder Criteria (PsARC), and Routine Assessment of Patient Index Data 3 (RAPID3). Further appraisal of candidate composite instruments is ongoing.

Original languageEnglish
Pages (from-to)53-57
Number of pages5
JournalThe Journal of Rheumatology
Volume50
Early online date7 Jul 2023
DOIs
Publication statusPublished - 1 Nov 2023

Funding

As part of the supplement series GRAPPA 2022, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. YYL is funded by the Clinician Scientist award of the National Medical Research Council (NMRC), Singapore (NMRC/CSA-INV/0022/2017). The views expressed are those of the author(s) and not necessarily those of the NMRC. AMO is funded by the Jerome L. Greene Foundation Scholar Award. AO is funded by the Rheumatology Research Foundation and National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases K23 AR063764 and R01 AR072363. RC (ie, the Parker Institute) is supported by a core grant from the Oak Foundation (OCAY-18-774-OFIL). JFM is funded by the National Psoriasis Foundation Psoriatic Disease Research Fellowship. LCC is funded by a National Institute of Health Research (NIHR) Research Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. 1Y.Y. Leung, MB ChB, MD, Duke-NUS Medical School, Singapore, Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; 2W. Tillett, BSc, MB ChB, PhD, Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; 3M. de Wit, PhD, GRAPPA Patient Research Partner, Amsterdam, the Netherlands; 4A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; 5L.C. Coates, MB ChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; 6O. FitzGerald, MD, Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; 7P.S. Helliwell, MD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; 8V. Strand, MD, Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; 9P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; 10N. Goel, MD, GRAPPA Patient Research Partner, and Therapeutic Area Head of Rheumatology, TrialSpark, and Duke University School of Medicine, Durham, North Carolina, USA; 11R. Christensen, MSc, PhD, Section for Biostatistics and Evidence-Based Research, The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, and Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; 12J.F. Merola, MD, MMSc, Harvard Medical School, Brigham and Women’s Hospital, Boston, Massachusetts, USA; 13C.A. Lindsay, PharmD, GRAPPA Patient Research Partner, Prosper, Texas, USA, employed by Arcutis Biotherapeutics Inc.; 14A. Ogdie, MD, MSCE, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; 15L. Gossec, MD, PhD, Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, and AP-HP, Pitié-Salpêtrière Hospital, Rheumatology Department, Paris, France; 16D.D. Gladman, MD, University of Toronto, Schroeder Arthritis Institute, Krembil Research Institute, and Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada. YYL has received speaker fees from AbbVie, DKSH, Janssen, Novartis, and Pfizer. WT has received research grants, speaker, or consulting fees from AbbVie, Amgen, Eli Lilly, GSK, Janssen, MSD, Novartis, Pfizer, and UCB. MDW has received fees for lectures over the past 3 years from Stichting Tools, and consulting fees from Celgene, Eli Lilly, Pfizer, and UCB.

FundersFunder number
National Institutes of Health
National Institute of Arthritis and Musculoskeletal and Skin DiseasesR01 AR072363, K23 AR063764
Oak FoundationOCAY-18-774-OFIL
National Psoriasis Foundation
Rheumatology Research Foundation
School of Public Health, University of California Berkeley
Jerome L. Greene Foundation
National Institute for Health and Care Research
National Medical Research CouncilNMRC/CSA-INV/0022/2017
NIHR Oxford Biomedical Research Centre

    Keywords

    • GRAPPA
    • composite outcome measures
    • outcome measures
    • physical function
    • psoriasis
    • psoriatic arthritis

    ASJC Scopus subject areas

    • Rheumatology
    • Immunology and Allergy
    • Immunology

    Access to Document

    Other files and links

      Fingerprint

      Dive into the research topics of 'Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group'. Together they form a unique fingerprint.
      View full fingerprint

      Cite this